<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513431</url>
  </required_header>
  <id_info>
    <org_study_id>RJBY_anti-CEA CAR-T_CRC01</org_study_id>
    <nct_id>NCT04513431</nct_id>
  </id_info>
  <brief_title>A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC)</brief_title>
  <acronym>CRC</acronym>
  <official_title>A Study Evaluating the Safety and Preliminary Efficacy of Anti-CEA CAR-T Cells for the Prevention of Postoperative Recurrence and Metastasis of Stage III Colorectal Cancer or Liver Metastasis of Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HuaDao (Shanghai) Biomedical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this research is to verify the safety of CEA targeted chimeric antigen&#xD;
      receptor T cells and to determine the proper dosage of CAR T cells infused.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chimeric antigen receptor (CAR)-modified T cells have demonstrated great successes in&#xD;
      treating even late stage cluster of differentiation antigen 19 (CD19) positive B cell&#xD;
      malignancies. But it has few studies in solid tumors. The carcino-embryonic antigen(CEA) is&#xD;
      widely expressed in cancers like gastric cancer, lung cancer, pancreatic cancer, breast&#xD;
      cancer and colorectal cancer. To confirm if CAR T cells still function in solid tumors, we&#xD;
      have developed anti-CEA CAR-modified T cells. Preclinical studies have demonstrated effective&#xD;
      killing of CEA target cells. In this study, the CEA CARs, will be evaluated in CEA positive&#xD;
      gastric cancer. The primary goal is to confirm its adverse effects including cytokine storm&#xD;
      response and any other adverse effects. In addition, tumor targeting and disease status after&#xD;
      treatment will also be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events that related to treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival time of Anti-CEA CAR T cells in vivo.</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate the presence of circulating CAR T cells with flow cytometry and real time PCR in patient blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of anti-CEA CAR T cells to confirm the ability of CAR T cells to kill CEA positive cancer cells</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the presence of circulating tumor cells with flow cytometry and real time PCR in patient blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose (MTD) of CEA targeted CAR T cells</measure>
    <time_frame>4 weeks</time_frame>
    <description>To confirm the maximum tolerated dose of CEA targeted CAR T cells.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Stage III Colorectal Cancer</condition>
  <condition>Colorectal Cancer Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>Colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CEA-CAR T</intervention_name>
    <description>T cells modified with CEA targeted chimeric antigen receptor.</description>
    <arm_group_label>Colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. CEA positive T4/N2 high-risk stage-Ⅲ colorectal cancer after surgery or patients with&#xD;
             colorectal cancer liver metastasis after R0 surgery;&#xD;
&#xD;
          2. Patients whose serum CEA ≥11 ng/mL;&#xD;
&#xD;
          3. Life expectancy ≥ 3 months;&#xD;
&#xD;
          4. PS score 0-2, KPS score ≥60;&#xD;
&#xD;
          5. &gt;3 CTC/7.5 mL blood sample;&#xD;
&#xD;
          6. Patients who plan to use XELOX chemotherapy after surgery;&#xD;
&#xD;
          7. Patients must have adequate organ function , such as NYHA heart function&#xD;
             classification grade III or higher, no severe anemia, hypoxia; liver function: total&#xD;
             bilirubin ≤ 1.5 × ULN (total bilirubin ≤ 3 × ULN when liver metastasis), ALT≤2.5×ULN,&#xD;
             AST≤2.5×ULN (ALT or/and AST≤5×ULN when liver metastasis); renal function: blood&#xD;
             creatinine ≤1.5 × ULN and creatinine clearance ≥50 mL/min, only when blood creatinine&#xD;
             ≤ Calculate the creatinine clearance rate when 1.5 × ULN;&#xD;
&#xD;
          8. Sufficient peripheral blood can be obtained through peripheral veins without&#xD;
             contraindications to apheresis;&#xD;
&#xD;
          9. Patients of childbearing age have no birth plans and take effective contraceptive&#xD;
             measures during the study period and within 1 year after the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have a history of severe central nervous system disease;&#xD;
&#xD;
          2. Other organ metastases except liver;&#xD;
&#xD;
          3. Patients who have non malignant diseases, including autoimmune diseases, primary&#xD;
             immunodeficiency diseases or obstructive or restrictive respiratory diseases;&#xD;
&#xD;
          4. Patients received car-t or other gene modified T cell therapy previously;&#xD;
&#xD;
          5. Patients who plan to use other targeted anti-tumor drugs;&#xD;
&#xD;
          6. Patients who participated in other clinical studies within 30 days before screening or&#xD;
             planned to participate in other clinical studies during the study period;&#xD;
&#xD;
          7. Patients who have syphilis or HIV / HBV / HCV / HPV / EBV / CMV infection ; HBV-DNA&#xD;
             copy number ≥ 1 × 10 ^ 5 copies / ml is required for HBV seropositive patients;&#xD;
&#xD;
          8. Patients who have uncontrollable systemic infectious diseases;&#xD;
&#xD;
          9. Patients who have multiple malignant tumor;&#xD;
&#xD;
         10. Patients who received or may need Chinese herbal medicine, systemic glucocorticoid or&#xD;
             other immunosuppressants within 2 weeks before enrollment;&#xD;
&#xD;
         11. Patient who are pregnancy and lactating;&#xD;
&#xD;
         12. Patients who have severe gastroduodenal ulcer, ulcerative colitis and other intestinal&#xD;
             inflammation;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ren Zhao, Medical PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mei Wang, Medical PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen xianze, Medical PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liu Kun, Medical PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shi Yiqing, Medical PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wang Chen, Medical PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>He Qianyun, Medical PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mao Dongliang, Medical PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei Wang, Medical PhD</last_name>
    <phone>+86-13601810867</phone>
    <email>13601810867@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Tian, Medical PhD</last_name>
    <phone>13651760950</phone>
    <email>lin.tian@huadaocart.com</email>
  </overall_contact_backup>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Mei Wang</investigator_full_name>
    <investigator_title>Director of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

